Database : MEDLINE
Search on : neoplasms [Words]
References found : 2203018 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 220302 go to page                         

  1 / 2203018 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 27797135
[Au] Autor:Seely JM; Verma R; Kielar A; Smyth KR; Hack K; Taljaard M; Gravel D; Ellison E
[Ad] Address:Department of Medical Imaging, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada. jeseely@ottawahospital.on.ca.
[Ti] Title:Benign Papillomas of the Breast Diagnosed on Large-Gauge Vacuum Biopsy compared with 14 Gauge Core Needle Biopsy - Do they require surgical excision?
[So] Source:Breast J;, 2016 Oct 31.
[Is] ISSN:1524-4741
[Cp] Country of publication:United States
[La] Language:ENG
[Ab] Abstract:To evaluate whether biopsy with vacuum-assisted biopsy (VAB) devices improves histologic underestimation rates of benign papillomas when compared to smaller bore core needle biopsy (CNB) devices. Patients with biopsy-proven benign papillomas with surgical resection or minimum 12 months follow-up were selected. Two breast pathologists reviewed all pathology slides of percutaneous and excisional biopsy specimens. Histologic underestimation rates for lesions biopsied with 10-12 Gauge (G) VAB were compared to those with 14G CNB. A total of 107 benign papillomas in 107 patients from two centers were included. There were 60 patients (mean age 57 years, SD 10.3 years) diagnosed with VAB and 47 patients (mean age 57.6 years, SD 11.3 years) with 14G CNB who underwent surgical excision or imaging follow-up. The upgrade rate to ductal carcinoma in situ or invasive carcinoma was 1.6% (1/60) with VAB and 8.5% (4/47) with 14G. Upgrade to atypia was 3.3% (2/60) after VAB and 10.6% (5/47) with CNB. The total underestimation rates were 5% (3/60) with VAB and 19.1% (9/47) with CNB. The odds of an upgrade to malignancy was 5.5 times higher with a 14G needle than VAB (95% CI: 0.592-50.853, p = 0.17). We observed a lower but not statistically significant upgrade rate to malignancy and atypia with the use of the 10-12 G VAB as compared with 14G CNB. When a papilloma without atypia is diagnosed with vacuum biopsy there is a high likelihood that it is benign; however, if surgical excision is not performed, long-term follow-up is still required.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1610
[Cu] Class update date: 161031
[Lr] Last revision date:161031
[St] Status:Publisher
[do] DOI:10.1111/tbj.12702

  2 / 2203018 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 27796764
[Au] Autor:David S; András F; Endre K; Balint K; Árpad K; Csaba P; Karoly S; Tamás T
[Ad] Address:Faculty of Medicine, Department of Pathology 2nd Diagnostic Laboratory, Rákóczi u 2, PÉCS, H-7624, Hungary. semjen.david@pte.hu.
[Ti] Title:More Cases of Benign Testicular Teratomas are Detected in Adults than in Children. A Clinicopathological Study of 543 Testicular Germ Cell Tumor Cases.
[So] Source:Pathol Oncol Res;, 2016 Oct 28.
[Is] ISSN:1532-2807
[Cp] Country of publication:Netherlands
[La] Language:ENG
[Ab] Abstract:Benign testicular teratomas are always thought to be pediatric neoplasms and previously all the teratoid tumors in the adult testis regarded as malignant. Recently, three publications reported benign testicular teratomas in adulthood and the latest WHO classification refers them as "prepubertal type of teratomas" which rarely appear in adulthood. These neoplasms behave benign and seemingly analogous independently whether they appear in pre- or postpubertal patients. The aim of our study was to investigate the frequency of benign testicular teratomas both in children and adults. 593 cases of testicular neoplasms were found in a period of 17 years ranging from 1998 to 2014 in the archive of our department (Department of Pathology, Medical Center, Pécs University). 543 cases diagnosed as germ cell tumor which have all been further evaluated in conjunction with the clinical data available. Of all germ cell tumor cases 14 (2.5 %) were pure teratomas. Ten out of 14 were the WHO-defined "conventional" teratoma, 4 of the 14 were the "benign or the so called prepubertal type" from which three occurred in adult patients. Only one of the 14 occurred in childhood, indicating that benign prepubertal type teratomas -which are regarded generally as childhood tumors- are more frequently detected in adults than in children. Benign adult testicular teratomas comprised 21 % of all pure teratoma cases in our series. Practicioners in the field have to be aware of its existence also in adulthood to avoid overtreatment and not to expose their patients to unnecessary chemotherapy, retroperitoneal lymphadenectomy (RLA) and the potential complications of these interventions.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1610
[Cu] Class update date: 161031
[Lr] Last revision date:161031
[St] Status:Publisher

  3 / 2203018 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 27796499
[Au] Autor:Mullally A
[Ad] Address:Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, 02115, Boston, MA, USA. amullally@partners.org.
[Ti] Title:Grundlegende Mechanismen der JAK2V617F-Mutation bei der Pathogenese myeloproliferativer Neoplasien. Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms.
[So] Source:Pathologe;, 2016 Oct 31.
[Is] ISSN:1432-1963
[Cp] Country of publication:Germany
[La] Language:ENG
[Ab] Abstract:Chronic myeloproliferative neoplasms (MPN) comprise a spectrum of clonal neoplastic disorders characterized by overproduction of terminally differentiated cells of the myeloid lineage. A common genetic basis for the BCR-ABL-negative MPN disorders was elucidated in 2005 with the identification of the JAK2V617F mutation in the majority of MPN patients. The discovery of JAK2V617F had a dramatic impact on the diagnosis and treatment of MPN. Testing for JAK2 mutations is now included in the World Health Organization (WHO) criteria for the diagnosis of MPN, and in 2011 the oral JAK2 kinase inhibitor ruxolitinib became the first Food and Drug Administration (FDA)-approved drug for the treatment of myelofibrosis. The drug is now also approved in Europe and Canada.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1610
[Cu] Class update date: 161031
[Lr] Last revision date:161031
[St] Status:Publisher

  4 / 2203018 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 27796129
[Au] Autor:Marton I; Simon Z; Borbényi Z
[Ad] Address:II. Belgyógyászati Klinika és Kardiológiai Központ, Haematológiai Osztály, Szegedi Tudományegyetem, Általános Orvostudományi Kar Szeged, Semmelweis u. 8., 6725.
[Ti] Title:Újdonságok, aktualitások a polycythaemia vera diagnosztikájában és kezelésében. [Diagnosis and treatment of polycythaemia vera: state of the art].
[So] Source:Orv Hetil;157(44):1743-1751, 2016 Oct.
[Is] ISSN:0030-6002
[Cp] Country of publication:Hungary
[La] Language:HUN
[Ab] Abstract:Polycythaemia vera (PV), a condition characterized by blood hyperviscosity due to the expansion of the erythrocyte mass is the most common entity among all Philadelphia chromosome-negative myeloproliferative neoplasms. Arterial and venous thrombotic events are leading determinants of morbidity and mortality but impairment of quality of life due to vasomotor symptoms (erythromelalgia, pruritus) and disease-associated symptoms (tiredness, fatigue, pruritus, night sweats, vision problems, headache, concentration loss, abdominal discomfort, early satiety, fever, weight loss) are also present. The review of polycythaemia vera is actual as the updated WHO 2016 classification of myeloid neoplasms has changed the diagnostic criteria and a new second-line treatment option - JAK1/JAK2 inhibitor ruxolitinib - has been approved for patients who had an inadequate response to or are intolerant of hydroxyurea, which represents a breakthrough in the treatment of this patient population. Orv. Hetil., 2016, 157(44), 1743-1751.
[Pt] Publication type:JOURNAL ARTICLE; ENGLISH ABSTRACT
[Em] Entry month:1610
[Cu] Class update date: 161031
[Lr] Last revision date:161031
[St] Status:In-Data-Review

  5 / 2203018 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 27795843
[Au] Autor:Guller AE; Grebenyuk PN; Shekhter AB; Zvyagin AV; Deyev SM
[Ad] Address:Macquarie University, Sydney, 2109, New South Wales, Australia ; ARC Centre of Excellence for Nanoscale BioPhotonics, Macquarie University, Sydney 2109, New South Wales, Australia ; Sechenov First Moscow State Medical University, Institute for Regenerative Medicine, 8, Trubetskaya Str., Moscow, 1199
[Ti] Title:Bioreactor-Based Tumor Tissue Engineering.
[So] Source:Acta Naturae;8(3):44-58, 2016 Jul-Sep.
[Is] ISSN:2075-8251
[Cp] Country of publication:Russia (Federation)
[La] Language:ENG
[Ab] Abstract:This review focuses on modeling of cancer tumors using tissue engineering technology. Tumor tissue engineering (TTE) is a new method of three-dimensional (3D) simulation of malignant neoplasms. Design and development of complex tissue engineering constructs (TECs) that include cancer cells, cell-bearing scaffolds acting as the extracellular matrix, and other components of the tumor microenvironment is at the core of this approach. Although TECs can be transplanted into laboratory animals, the specific aim of TTE is the most realistic reproduction and long-term maintenance of the simulated tumor properties in vitro for cancer biology research and for the development of new methods of diagnosis and treatment of malignant neoplasms. Successful implementation of this challenging idea depends on bioreactor technology, which will enable optimization of culture conditions and control of tumor TECs development. In this review, we analyze the most popular bioreactor types in TTE and the emerging applications.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1610
[Cu] Class update date: 161031
[Lr] Last revision date:161031
[St] Status:In-Data-Review

  6 / 2203018 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 27795812
[Au] Autor:Moschovis D; Bamias G; Delladetsima I
[Ad] Address:Dimitrios Moschovis, Department of Gastroenterology, Agios Panteleimon General Hospital, 18453 Nikea, Greece.
[Ti] Title:Mucins in neoplasms of pancreas, ampulla of Vater and biliary system.
[So] Source:World J Gastrointest Oncol;8(10):725-734, 2016 Oct 15.
[Cp] Country of publication:China
[La] Language:ENG
[Ab] Abstract:Tumors of the pancreas, the ampulla of Vater, and the extrahepatic and intrahepatic bile ducts have significant histological similarities due to the common embryonic origin of the pancreatobiliary system. This obviates the need for discovery of biomarkers with diagnostic and prognostic value for these tumors. Mucins, especially MUC-1, -2, -4 and -5AC, are important candidates for developing into such reliable biomarkers. Increased expression of MUC1 occurs in pancreatic ductal adenocarcinomas and is associated with increased degrees of dysplasia in pancreatic intraepithelial neoplasia (PanIN). Positive expression of MUC2 in intraductal papillary mucinus neoplasms (IPMN) of the intestinal type indicates high potential progression to invasive carcinoma with de novo expression of MUC1, while absence of MUC2 expression in IPMNs of gastric type implies low potential to malignant evolution. De novo MUC4 expression correlates to the severity of dysplasia in PanIN and is associated with a poor prognosis in patients with pancreatic ductal adenocarcinomas. In biliary intraepithelial neoplasia (BilIN), increased expression of MUC1 is associated with higher degrees of dysplasia. Intrahepatic cholangiocarcinomas (ICC) are characterized by increased expression of all glycoforms of MUC1. Positive MUC2 expression in intraductal papillary neoplasm of the bile ducts (IPNB) of the intestinal type indicates high malignant potential with de novo expression of MUC1 in the invasive element. Absent MUC2 expression in any degree of BilIN may prove useful in differentiating them from IPNB. De novo expression of MUC4 is associated with poor prognosis in patients with ICC or carcinoma of the extrahepatic bile ducts (EHBDC). High de novo expression of MUC5AC is found in all degrees of BilIN and all types of IPNB and ICC. The MUC5AC is useful in the detection of neoplastic lesions of the bile duct at an early stage. Increased expression of mucin MUC1 in carcinoma of the ampulla of Vater associated with unfavorable behavior of the tumor, such as lymph node metastasis, infiltration of the pancreas and duodenum, advanced TNM classification and worse prognosis. Patients with intra-ampullary papillary-tubular neoplasm (IAPN) of the pancreatobiliary immunophenotype did not show MUC2, while those of the intestinal immunophenotype are MUC2 positive. The expression of MUC4 is associated with poor prognosis in patients with carcinoma of the ampulla of Vater favoring metastasis and making them resistant to apoptosis. Moreover, it appears that MUC4 positivity correlates with recurrence of the tumor. Expression of MUC5AC is associated with the invasive potential of the tumor.
[Pt] Publication type:REVIEW; JOURNAL ARTICLE
[Em] Entry month:1610
[Cu] Class update date: 161031
[Lr] Last revision date:161031
[St] Status:In-Data-Review

  7 / 2203018 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 27795759
[Au] Autor:Boujoual M; Hakimi I; Kassidi F; Akhoudad Y; Sahel N; Rkiouak A; Allaoui M; Chahdi H; Oukabli M; Kouach J; Moussaoui DR; Dehayni M
[Ad] Address:Department of Gynecology-Obstetric, University of Medicine Tangier, Military Training Hospital Med V, Rabat, Maroc.
[Ti] Title:Paraneoplastic syndromes revealing ovarian teratoma in young and menopausal women: report of two cases.
[So] Source:Pan Afr Med J;24:161, 2016.
[Is] ISSN:1937-8688
[Cp] Country of publication:Uganda
[La] Language:ENG
[Ab] Abstract:Paraneoplastic syndromes are a heterogeneous group of clinical and biological manifestations caused by underling neoplasms. They can reveal ovarian teratoma which express neuroendocrine proteins, or contain mature or immature neural tissue inducing an autoimmune response. The etiological investigation is then crucial to early identification of the tumor in order to optimize the prognosis and to limit neurological sequelae. In case of ovarian teratoma, management is essentially based on surgical resection sometimes associated with immunotherapie. We report two new cases of ovarian teratoma revealed by paraneoplastic syndromes in young and menopausal woman.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1610
[Cu] Class update date: 161031
[Lr] Last revision date:161031
[St] Status:In-Data-Review

  8 / 2203018 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 27795651
[Au] Autor:Desai D; Pandit S; Jasphin S; Shetty AS
[Ad] Address:Department of Oral and Maxillofacial Pathology and Microbiology, AJ Institute of Dental Sciences, Manipal, Karnataka, India.
[Ti] Title:Human immunodeficiency virus associated plasmablastic lymphoma: A case report.
[So] Source:Indian J Dent;7(3):144-148, 2016 Sep.
[Is] ISSN:0975-962X
[Cp] Country of publication:India
[La] Language:ENG
[Ab] Abstract:Non-Hodgkin's lymphoma (NHL) is the third common malignant lesion of the oral region. Plasmablastic lymphomas are rare, aggressive neoplasms occurring mostly in human immunodeficiency virus (HIV) infected individual which accounts for approximately 2.6% of all NHL. It usually presents as a diffuse growth and with diffuse pattern of histological presentation. It is very difficult to differentiate this lymphoma from other NHL. Immunohistochemical evaluation of various markers is an important criteria of the diagnostic protocol. Here, we describe a case of plasmablastic lymphoma in a 50-year-old female HIV-infected patient. The diagnosis was based on histopathological examination and immunophenotyping.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1610
[Cu] Class update date: 161031
[Lr] Last revision date:161031
[St] Status:In-Data-Review

  9 / 2203018 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27795560
[Au] Autor:Troadec E; Dobbelstein S; Bertrand P; Faumont N; Trimoreau F; Touati M; Chauzeix J; Petit B; Bordessoule D; Feuillard J; Bastard C; Gachard N
[Ad] Address:Laboratoire d'Hématologie, CBRS, CHU de Limoges et UMR CNRS 7276, Limoges, France.
[Ti] Title:A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: Toward myeloid/lymphoid neoplasms with eosinophilia and rearrangement of FLT3?
[So] Source:Leukemia;, 2016 Oct 31.
[Is] ISSN:1476-5551
[Cp] Country of publication:England
[La] Language:ENG
[Ab] Abstract:Leukemia accepted article preview online, 31 October 2016. doi:10.1038/leu.2016.304.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1610
[Cu] Class update date: 161031
[Lr] Last revision date:161031
[St] Status:Publisher
[do] DOI:10.1038/leu.2016.304

  10 / 2203018 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 27795447
[Au] Autor:Yeung WW; Ma BB; Lee JF; Ng SS; Cheung MH; Ho WM; Tsang MW; Chu S; Lam DC; Mo FK
[Ad] Address:Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong.
[Ti] Title:Clinical outcome of neoadjuvant chemoradiation in locally advanced rectal cancer at a tertiary hospital.
[So] Source:Hong Kong Med J;, 2016 Oct 31.
[Is] ISSN:1024-2708
[Cp] Country of publication:China
[La] Language:ENG
[Ab] Abstract:OBJECTIVES: To review the clinical outcome of locally advanced rectal cancer treated with neoadjuvant chemoradiation followed by definitive surgery with or without adjuvant chemotherapy and to elucidate the prognostic factors for treatment outcome. METHODS: This historical cohort study was conducted at a tertiary public hospital in Hong Kong. All patients who had undergone neoadjuvant chemoradiation for locally advanced rectal cancer in our department from November 2005 to October 2014 were recruited. Local recurrence-free survival, distant metastasis-free survival, disease-free survival, and overall survival of patients were documented. RESULTS: A total of 135 patients who had received neoadjuvant chemoradiation during the study period were reviewed. There were 130 patients who had completed neoadjuvant chemoradiation and surgery. The median follow-up time was 35.1 months. The 3- and 5-year local recurrence-free survival, distant metastasis-free survival, disease-free survival, as well as overall survival rates were 91.8% and 86.7%, 73.9% and 72.1%, 70.1% and 64.6%, as well as 86.5% and 68.4%, respectively. The rate of pathological complete response was 13.8%. The T and N downstaging rate was 49.2% and 63.1%, respectively. The rate of conversion from threatened circumferential resection margin to clearance of margin was 90.6%. Of the 42 cases that were initially deemed to require abdominal perineal resection, 15 (35.7%) were converted to sphincter-sparing surgery. CONCLUSIONS: The treatment outcome of neoadjuvant chemoradiation for locally advanced rectal cancer was comparable with overseas data in terms of local control rate and overall survival. This strategy may increase the chance of achieving a clear surgical margin by downstaging the tumour, especially in patients who presented with threatened circumferential margin.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1610
[Cu] Class update date: 161031
[Lr] Last revision date:161031
[St] Status:Publisher
[do] DOI:10.12809/hkmj154788


page 1 of 220302 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information